Searchable abstracts of presentations at key conferences in endocrinology

ea0035p716 | Neuroendocrinology | ECE2014

Long-term remission and recurrence rates after transsphenoidal surgery for cushing's disease

Moreno Paloma Moreno , Fernandez Julia Silva , Exposito Maria Rosa Alhambra , Moreno Maria angeles Galvez

Objective: Transsphenoidal surgery (TSS) presents the treatment of choice for Cushing’s disease (CD), 95% microadenomas. Remission and recurrence rates vary dependent on tumor size, extension, adenoma visibility on magnetic resonance imaging, and neurosurgical expertise. Remission rates in the postoperative vary between 55 and 85%, with a recurrence of up to 25%. The aim of this study was to describe the rate of remission and recurrence of CD in our midst after TSS, and c...

ea0029p1139 | Neuroendocrinology | ICEECE2012

Pituitary incidentaloma: clinical presentation and endocrine evaluation in a Spanish population

Alhambra Exposito M. , Galvez Moreno M. , Tenorio Jimenez C. , Moreno Moreno P. , Benito Lopez P.

Introduction: The incidence of previously unrecognized lesions within the pituitary has been studied by MRI. The data suggest that up to 10% of people have clinically unsuspected pituitary tumors, the majority being<10 mm. Currently, little information is available about the prevalence of incidentally-discovered sellar masses.Objective: To perform a clinical audit on pituitary incidentalomas in order to establish an appropriate clinical approach to t...

ea0026p467 | Thyroid cancer | ECE2011

Differences between incidental and preoperatively diagnosed papillary thyroid microcarcinomas. Review of the last decade

Paja M , Oleaga A , Ugalde A , Exposito A , Moreno C , Sanchez-Goitia M , Izuzquiza A J , Elorza J R

Increasing incidence of papillary thyroid microcarcinoma (PTMC) is due to accurate histological study of surgical specimens (incidental, INC) or to improved preoperative diagnostic techniques (preoperatively diagnosed, PD). We evaluate the differences between both groups of PTMC from 2000 to 2009.We reviewed data of patients diagnosed of PTMC (<10 mm) during the last decade with complete follow-up since surgery. Demographic data, tumour size, histolo...

ea0056p484 | Diabetes therapy | ECE2018

Dapagliflozin after liraglutide in patients with type 2 diabetes

Moreno-Moreno Paloma , Munoz-Jimenez Concepcion , Alhambra-Exposito Maria Rosa , Galvez-Moreno Maria Angeles

Objective: To evaluate the efficacy of dapagliflozin for glycemic control and progression of weight loss after stabilization with liraglutide 1.8 mg.Patients and methods: Descriptive study: patients with tipo 2 diabetes (DM-2) in treatment with metformin and liraglutide 1.8 mg, optimal metabolic control, which after stabilization in weight loss, liraglutide is suspended and dapagliflozin is added. Variables analyzed baseline and at 6 months after treatme...

ea0056p485 | Diabetes therapy | ECE2018

Canagliflozin after liraglutide in patients with type 2 diabetes

Moreno-Moreno Paloma , Alhambra-Exposito Maria Rosa , Munoz-Jimenez Concepcion , Galvez-Moreno Maria Angeles

Objective: To evaluate the efficacy of canagliflozin 100 mg for glycemic control and progression of weight loss after stabilization with liraglutide 1.8 mg.Patients and methods: Descriptive study: patients with type 2 diabetes (DM-2) in treatment with metformin and liraglutide 1.8 mg, optimal metabolic control, which after stabilization in weight loss, liraglutide is suspended and canagliflozin 100 mg is added. Variables analyzed baseline and at 6 months...

ea0056p486 | Diabetes therapy | ECE2018

Inhibitors SGLT2 after liraglutide in patients with type 2 diabetes

Moreno-Moreno Paloma , Munoz-Jimenez Concepcion , Alhambra-Exposito Maria Rosa , Galvez-Moreno Maria Angeles

Objetive: The change of treatment of liraglutide 1.8 mg to dapagliflozin or canaglifonzin 100 mg in patients with optimal glycemic control and stabilization weight loss, achieves progression in weight loss and improves the metabolic control of the patient with tipo 2 diabetes (DM-2). Our objective is to evaluate if there are differences in metabolic control and progression of weight loss in patients treated with canagliflozin 100 mg or dapagliflozin.Pati...

ea0056p555 | Obesity | ECE2018

Are there differences in cardiovascular risk between metabolically healthy and sick obese?

Rosa Alhambra Exposito Maria , Munoz Jimenez Concepcion , Calanas Continente Alfonso , Jose Molina Puerta Maria

Introduction: Obesity is a major health problem and a risk factor for the development of other diseases. However, there are morbid obese subjects of long evolution that can be considered metabolically healthy obese, whose existence is in doubt for many clinicians.Objetive: To analyze if there are differences in cardiovascular risk between metabolically healthy (MHO) and sick obese (MSO), matched by age, sex and body mass index (BMI).<p class="abstext...

ea0056p753 | Neuroendocrinology | ECE2018

Could predict the postoperative rosnance the acromegaly cure?

Rosa Alhambra Exposito Maria , Sagrario Lombardo Galera Maria , Rebollo Roman Angel , Angeles Galvez Moreno M.

Acromegaly is caused by excessive growth hormone (GH) secretion from pituitary adenomas. Transphenoidal surgery is the first-choice treatment, but new drug therapies (e.g. somatostatin analogs, SSA) offer promising avenues for medical treatment. Complementary diagnostic tools may assist this strategy, helping to refine drug choice. Here, we investigate the associations between postsurgical radiological features and molecular phenotype of pituitary tumors from acromegalic patie...

ea0081p662 | Pituitary and Neuroendocrinology | ECE2022

Inferior petrosal sinus sampling for pituitary neuroendocrine tumors localization in cushing’s disease

Moreno-Moreno Paloma , Rosa Alhambra Exposito Ma , Rebollo-Roman Angel , Herrera-Martinez Aura D. , Angeles Galvez-Moreno Maria

Objective: Cushing’s disease (CD) is the most common cause of hypercortisolism after iatrogenic origin, it represents approximately 70% of patients with endogenous Cushing’s syndrome (CS) and ectopic ACTH secretion (10%). CD is caused by a corticotropin-secreting pituitary neuroendocrine tumor (ACTH-secreting Pit-NETs), 95% of cases as a microadenoma. In ACTH-dependent CS, differential diagnosis between CD and ectopic CS must be established. 40% of CD cases, any tumo...

ea0063gp207 | Diabetes: Pharmacotherapy | ECE2019

Treatment with sitagliptin in patients with type 1 diabetes and type LADA diabetes

Moreno-Moreno Paloma , Alhambra-Exposito Maria Rosa , Rebollo-Roman Angel , Martin-Barrera Ana , Galvez-Moreno Maria Angeles

Objective: Preclinical studies have shown that DPP-4 inhibitors (iDPP4) have beneficial effects on functional mass of beta cells and pancreatic insulin content. The aim of this study is to evaluate the efficacy of treatment with sitagliptin in monotherapy or in combination with insulin in person with type 1 diabetes (DM-1) or type LADA diabetes (DM-LADA) of recent diagnosis.Patients and methods: Descriptive study: patients with DM-1 or DM-LADA in treatme...